RT Journal Article SR Electronic T1 Burden, Causation, and Particularities of long-COVID in African populations: A rapid systematic review JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2023.01.13.23284305 DO 10.1101/2023.01.13.23284305 A1 Nyasulu, Peter S. A1 Tamuzi, Jacques L. A1 Erasmus, Rajiv T. YR 2023 UL http://medrxiv.org/content/early/2023/01/13/2023.01.13.23284305.abstract AB Background The global estimated prevalence of long COVID-19 is 43%, and the most common symptoms found globally are fatigue, confusion, or lack of confusion, and dyspnea, with prevalence rates of 23%, 14%, and 13%, respectively. However, long COVID still lacks an overall review in African populations. The aim of this review was to determine the prevalence of long COVID, its most common symptoms, comorbidities, and pathophysiological mechanisms.Methods A systematic review of long COVID in African populations was conducted. The random effects model was used to calculate the pooled prevalence rates (95% CI). If the results could not be pooled, a narrative synthesis was performed.Results We included 14 studies from 7 African countries, totaling 6,030 previously SARS-CoV-2 infected participants and 2,954 long COVID patients. Long COVID had a pooled prevalence of 41% [26%-56%]. Fatigue, dyspnea, and confusion or lack of concentration were the most common symptoms, with prevalence rates (95% CI) of 41% [26%-56%], 25% [12%-38%], and 40% [12%-68%], respectively. Long COVID was associated with advanced age, being female, more than three long COVID symptoms in the acute phase, initial fatigue and dyspnea, post-recovery stress, sadness, and sleep disturbances, and loss of appetite at symptoms onset, mild, moderate, and severe, pre-existing obesity, hypertension, diabetes mellitus, and the presence of any chronic illness (P ≤0.05). According to our review, high micro clot and platelet poor plasma (PPP) viscosity explain the pathophysiology of long COVID.Conclusion Long COVID prevalence in Africa was comparable to the global prevalence. However, the prevalence of the most common symptoms was higher in Africa. Comorbidities associated with long COVID may lead to additional complications in African populations due to hypercoagulation and thrombosis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript-2AP-2 antiplasminACE2Angiotensin-Converting Enzyme 2AIDSacquired immune deficiency syndromeARDSacute respiratory distress syndromeBMIbody mass indexCDCCenters for Disease Control and PreventionCCSChronic COVID syndromeCFSchronic fatigue syndromeCOPDChronic obstructive pulmonary diseaseCOVID-19Coronavirus disease 2019E-selectinendothelial-leukocyte adhesion molecule 1GORDGastroesophageal reflux diseaseHIVhuman immunodeficiency virusHLAhuman leukocyte antigenICUintensive care unitMIS-Amulti-system inflammatory syndrome in adultsMISmultisystem inflammatory syndromeNICENational Institute for Health and Care ExcellencePASCPost-Acute Sequelae of SARS-CoV-2PECAM-1platelet endothelial cell adhesion molecule-1PLWHpersons living with HIVPF4platelet factor 4PPPplatelet poor plasmaRNAribonucleic acidRT-PCRReverse transcription polymerase chain reactionSAAserum Amyloid ASARS-CoV-2Severe acute respiratory syndrome coronavirus 2TBtuberculosisUNUnited NationsVWFVon Willebrand FactorWHOWorld Health Organization